Robotic Seed Implantation for Prostate Cancer Brachytherapy (EUCLIDIAN)
Phase I Study Using EUCLIDIAN Robotic Assistance During Prostate Brachytherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing)
The dose-volume histogram parameters of robotic brachytherapy will be compared to historical controls of the study institution. Short-term (<1 yr) health-related quality of life (HRQoL) and changes will be assessed using FACT-P and IPSS self-report questionnaires.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed, adenocarcinoma of the prostate, clinical stage T1c-T2b, NX, N0, M0.
- Zubrod status 0-1.
- Prostate tumor biopsy grading by Gleason score classification is mandatory prior to registration
- No prior pelvic radiation or chemotherapy for any reason; induction hormonal therapy beginning < or = 6 months prior to registration is acceptable.
- Prostate volume < or = 65 cc prior to registration, or planned use of LHRH agonist therapy for reduction of prostate volume. If LHRH agonist therapy is used to reduce prostate volume, then prostate volume must be < or = 65 cc on the routine pre-implant volume study to be eligible for the study.
- Gleason score 6, or Gleason Score 7 if both , or = 33% of biopsy cores contain cancer and PSA level is < or = 10 ng/mL.
- AUA voiding symptoms score < or = 15.
- Prostate specific antigen (PSA) prior to study entry (and prior to any hormone treatment if given); must be < or = 20 ng/ml.
- Patients must sign a study-specific consent form prior to registration (Standard of care: only the standard consent form must be signed).
- Patient must be > or = 40 years old.
Exclusion Criteria:
- Stage T2c, T3 or T4 disease.
- Lymph node involvement (pathological N1)
- Evidence of distant metastases (M1)
- Gleason score 8-10.
- Prostate specific antigen (PSA) prior to study entry > 20 ng/mL.
- AUA voiding symptoms score > 15.
- Radical surgery for carcinoma of the prostate.
- Previous hormonal therapy beginning > 6 months prior to registration
- Previous or concurrent cancers other than basal or squamous cell skin cancers unless disease- free for > or = 5 years.
- Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up and/or completion of HRQoL questionnaires (not a condition for ineligibility in Standard of care).
- Prior TURP
- Hip prosthesis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Implant
Robotic implantation of brachytherapy seeds to treat prostate cancer
|
EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coverage of the prostate by the prescribed radiation dose at V100
Time Frame: Day 0 and Day 30 post-implant
|
The principal endpoint is the dose-volume histogram (DVH) measured at V100 (percent volume of the target receiving the intended dose).
These values will also be compared retrospectively to those in the conventional group.
Improved quality will be demonstrated by increased V100 in the protocol patients.
|
Day 0 and Day 30 post-implant
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coverage of the prostate by the prescribed radiation dose at D90
Time Frame: 12 months post-treatment
|
The secondary endpoint is the dose-volume histogram (DVH) measured at D90 (dose to 90% of the target volume).
These values will also be compared retrospectively to those in the conventional group.
|
12 months post-treatment
|
|
Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Time Frame: 12 months
|
Patient self-reported, health-related, quality of life measures using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) self-report questionnaire.
FACT-P instruments prior to treatment (T0), 1 month (T1), 3 months (T3), 6 months (T6) and 12 months (T12) following treatment with robot-assisted brachytherapy.
|
12 months
|
|
International Prostate Symptom Score (IPSS)
Time Frame: 12 months
|
Patient self-reported, health-related, quality of life measures using the International Prostate Symptom Score (IPSS) self-report questionnaire.
IPSS instruments prior to treatment (T0), 1 month (T1), 3 months (T3), 6 months (T6) and 12 months (T12) following treatment with robot-assisted brachytherapy.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Adam Dicker, MD, PhD, Thomas Jefferson University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 08F.298
- 2007-24 (Other Identifier: CCRRC)
- R01CA091763 (U.S. NIH Grant/Contract)
- JT 1232 (Other Identifier: JeffTrial Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.